# Arcturus Therapeutics Holdings Inc.: financial statements, quarterly

ARCT · Nasdaq · CIK 1768224 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arct.md) · [Financials](/companies/arct/financials.md) · [Filings](/companies/arct/filings.md) · [Insiders](/companies/arct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [45.1](/filings/0000950170-24-123469.md) | [30.9 d](/filings/0001193125-26-088391.md) | [38.0](/filings/0000950170-25-069210.md) | [49.9](/filings/0000950170-25-106560.md) | [41.7](/filings/0001193125-25-275758.md) | [22.8 d](/filings/0001193125-26-088391.md) | [29.4](/filings/0001193125-26-211943.md) | [28.3](/filings/0001193125-26-338090.md) | [17.2](/filings/0001193125-25-275758.md) | [7.2 d](/filings/0001193125-26-088391.md) | [2.1](/filings/0001193125-26-211943.md) | [3.0](/filings/0001193125-26-338090.md) |
| Research and development | $m | [51.1](/filings/0000950170-24-123469.md) | [36.6 d](/filings/0001193125-26-088391.md) | [53.6](/filings/0000950170-25-069210.md) | [58.7](/filings/0000950170-25-106560.md) | [39.1](/filings/0001193125-25-275758.md) | [43.8 d](/filings/0001193125-26-088391.md) | [34.9](/filings/0001193125-26-211943.md) | [29.6](/filings/0001193125-26-338090.md) | [23.3](/filings/0001193125-25-275758.md) | [24.5 d](/filings/0001193125-26-088391.md) | [21.5](/filings/0001193125-26-211943.md) | [17.5](/filings/0001193125-26-338090.md) |
| Operating income | $m | [(19.3)](/filings/0000950170-24-123469.md) | [(18.3) d](/filings/0001193125-26-088391.md) | [(30.4)](/filings/0000950170-25-069210.md) | [(21.1)](/filings/0000950170-25-106560.md) | [(10.7)](/filings/0001193125-25-275758.md) | [(33.4) d](/filings/0001193125-26-088391.md) | [(16.8)](/filings/0001193125-26-211943.md) | [(11.6)](/filings/0001193125-26-338090.md) | [(16.5)](/filings/0001193125-25-275758.md) | [(31.3) d](/filings/0001193125-26-088391.md) | [(28.9)](/filings/0001193125-26-211943.md) | [(25.5)](/filings/0001193125-26-338090.md) |
| Income tax | $m | [0.9](/filings/0000950170-24-123469.md) | [0.3 d](/filings/0001193125-26-088391.md) | [0.4](/filings/0000950170-25-069210.md) | [(0.2)](/filings/0000950170-25-106560.md) | [(0.2)](/filings/0001193125-25-275758.md) | [(0.0) d](/filings/0001193125-26-088391.md) | [0.0](/filings/0000950170-25-069210.md) | [0.0](/filings/0001193125-26-338090.md) | [0.0 d](/filings/0001193125-25-275758.md) | not reported | not reported | [0.0](/filings/0001193125-26-338090.md) |
| Net income | $m | [(16.2)](/filings/0000950170-24-123469.md) | [(11.7) d](/filings/0001193125-26-088391.md) | [(26.8)](/filings/0001193125-25-275758.md) | [(17.2)](/filings/0001193125-25-275758.md) | [(6.9)](/filings/0001193125-25-275758.md) | [(30.0) d](/filings/0001193125-26-088391.md) | [(14.1)](/filings/0001193125-26-338090.md) | [(9.2)](/filings/0001193125-26-338090.md) | [(13.4)](/filings/0001193125-25-275758.md) | [(29.1) d](/filings/0001193125-26-088391.md) | [(27.0)](/filings/0001193125-26-338090.md) | [(23.8)](/filings/0001193125-26-338090.md) |
| Diluted EPS | $ per share | [(0.61)](/filings/0000950170-24-123469.md) | not reported | [(1.00)](/filings/0000950170-25-069210.md) | [(0.64)](/filings/0000950170-25-106560.md) | [(0.26)](/filings/0001193125-25-275758.md) | not reported | [(0.52)](/filings/0001193125-26-211943.md) | [(0.34)](/filings/0001193125-26-338090.md) | [(0.49)](/filings/0001193125-25-275758.md) | not reported | [(0.95)](/filings/0001193125-26-211943.md) | [(0.84)](/filings/0001193125-26-338090.md) |
| Basic EPS | $ per share | [(0.61)](/filings/0000950170-24-123469.md) | not reported | [(1.00)](/filings/0000950170-25-069210.md) | [(0.64)](/filings/0000950170-25-106560.md) | [(0.26)](/filings/0001193125-25-275758.md) | not reported | [(0.52)](/filings/0001193125-26-211943.md) | [(0.34)](/filings/0001193125-26-338090.md) | [(0.49)](/filings/0001193125-25-275758.md) | not reported | [(0.95)](/filings/0001193125-26-211943.md) | [(0.84)](/filings/0001193125-26-338090.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [312](/filings/0000950170-24-123469.md) | [292](/filings/0001193125-26-088391.md) | [288](/filings/0000950170-25-069210.md) | [260](/filings/0000950170-25-106560.md) | [237](/filings/0001193125-25-275758.md) | [237](/filings/0001193125-26-088391.md) | [217](/filings/0001193125-26-211943.md) | [196](/filings/0001193125-26-338090.md) | [180](/filings/0001193125-25-275758.md) | [231](/filings/0001193125-26-338090.md) | [211](/filings/0001193125-26-211943.md) | [191](/filings/0001193125-26-338090.md) |
| Current assets | $m | [393](/filings/0000950170-23-063778.md) | [387](/filings/0000950170-25-034787.md) | [376](/filings/0000950170-24-055702.md) | [347](/filings/0000950170-24-090905.md) | [331](/filings/0000950170-24-123469.md) | [306](/filings/0001193125-26-088391.md) | [279](/filings/0000950170-25-069210.md) | [275](/filings/0000950170-25-106560.md) | [249](/filings/0001193125-25-275758.md) | [241](/filings/0001193125-26-338090.md) | [217](/filings/0001193125-26-211943.md) | [197](/filings/0001193125-26-338090.md) |
| Total assets | $m | [458](/filings/0000950170-23-063778.md) | [429](/filings/0000950170-25-034787.md) | [419](/filings/0000950170-24-055702.md) | [389](/filings/0000950170-24-090905.md) | [371](/filings/0000950170-24-123469.md) | [344](/filings/0001193125-26-088391.md) | [332](/filings/0000950170-25-069210.md) | [309](/filings/0000950170-25-106560.md) | [282](/filings/0001193125-25-275758.md) | [271](/filings/0001193125-26-338090.md) | [245](/filings/0001193125-26-211943.md) | [224](/filings/0001193125-26-338090.md) |
| Current liabilities | $m | [87.7](/filings/0000950170-23-063778.md) | [82.0](/filings/0000950170-25-034787.md) | [115](/filings/0000950170-24-055702.md) | [91.7](/filings/0000950170-24-090905.md) | [69.5](/filings/0000950170-24-123469.md) | [65.5](/filings/0001193125-26-088391.md) | [49.4](/filings/0000950170-25-069210.md) | [46.5](/filings/0000950170-25-106560.md) | [31.7](/filings/0001193125-25-275758.md) | [36.4](/filings/0001193125-26-338090.md) | [34.4](/filings/0001193125-26-211943.md) | [33.5](/filings/0001193125-26-338090.md) |
| Total liabilities | $m | [178](/filings/0000950170-23-063778.md) | [151](/filings/0000950170-25-034787.md) | [155](/filings/0000950170-24-055702.md) | [130](/filings/0000950170-24-090905.md) | [109](/filings/0000950170-24-123469.md) | [103](/filings/0001193125-26-088391.md) | [98.0](/filings/0000950170-25-069210.md) | [78.2](/filings/0000950170-25-106560.md) | [57.8](/filings/0001193125-25-275758.md) | [57.2](/filings/0001193125-26-338090.md) | [54.0](/filings/0001193125-26-211943.md) | [52.5](/filings/0001193125-26-338090.md) |
| Long-term debt | $m | [20.0](/filings/0000950170-23-063778.md) | not reported | not reported | not reported | not reported | not reported | [15.0](/filings/0000950170-25-069210.md) | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [280](/filings/0000950170-24-123469.md) | [279](/filings/0001193125-26-088391.md) | [264](/filings/0001193125-25-275758.md) | [259](/filings/0001193125-25-275758.md) | [262](/filings/0001193125-25-275758.md) | [241](/filings/0001193125-26-338090.md) | [234](/filings/0001193125-26-338090.md) | [231](/filings/0001193125-26-338090.md) | [225](/filings/0001193125-25-275758.md) | [214](/filings/0001193125-26-338090.md) | [191](/filings/0001193125-26-338090.md) | [172](/filings/0001193125-26-338090.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.4) d](/filings/0000950170-24-123469.md) | [(0.6) d](/filings/0001193125-26-088391.md) | [(5.6)](/filings/0000950170-25-069210.md) | [(30.1) d](/filings/0000950170-25-106560.md) | [(23.8) d](/filings/0001193125-25-275758.md) | [(0.3) d](/filings/0001193125-26-088391.md) | [(35.1)](/filings/0001193125-26-211943.md) | [(5.8) d](/filings/0001193125-26-338090.md) | [(17.2) d](/filings/0001193125-25-275758.md) | [(16.2) d](/filings/0001193125-26-088391.md) | [(19.4)](/filings/0001193125-26-211943.md) | [(19.9) d](/filings/0001193125-26-338090.md) |
| Capital expenditure | $m | [1.0 d](/filings/0000950170-24-123469.md) | [0.9 d](/filings/0001193125-26-088391.md) | [0.2](/filings/0000950170-25-069210.md) | [0.3 d](/filings/0000950170-25-106560.md) | [0.1 d](/filings/0001193125-25-275758.md) | [0.0 d](/filings/0001193125-26-088391.md) | [0.1](/filings/0001193125-26-211943.md) | [0.0 d](/filings/0001193125-26-338090.md) | [0.2 d](/filings/0001193125-25-275758.md) | [(0.1) d](/filings/0001193125-26-088391.md) | [0.0](/filings/0001193125-26-211943.md) | [0.0 d](/filings/0001193125-26-338090.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-063778.md) | [27.1](/filings/0000950170-24-055702.md) | [26.6](/filings/0000950170-24-090905.md) | [26.6](/filings/0000950170-24-123469.md) | [26.9](/filings/0000950170-25-069210.md) | [27.0](/filings/0000950170-25-106560.md) | [27.1](/filings/0001193125-25-275758.md) | [27.1](/filings/0001193125-26-211943.md) | [27.1](/filings/0001193125-26-338090.md) | [27.2](/filings/0001193125-25-275758.md) | [28.4](/filings/0001193125-26-211943.md) | [28.4](/filings/0001193125-26-338090.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,423,069 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338090.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.